6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2022.

Commission File Number: 001-40852

 

 

LUMIRADX LIMITED

(Translation of registrant’s name into English)

 

 

LumiraDx Limited

c/o Ocorian Trust (Cayman) Limited

PO Box 1350, Windward 3, Regatta Office Park

Grand Cayman KY1-1108

Cayman Islands

(354) 640-0540

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


EXPLANATORY NOTE

On June 21, 2022, LumiraDx Limited used an updated corporate presentation at its investor day event, a copy of which is attached hereto as Exhibit 99.1. The fact that this presentation is being made available and filed herewith is not an admission as to the materiality of any information contained in the presentation.

EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Investor presentation, dated June 21 2022, furnished herewith.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    LUMIRADX LIMITED
Date: June 21, 2022      
    By:  

/s/ Dorian LeBlanc

    Name:   Dorian LeBlanc
    Title:   Chief Financial Officer
EX-99.1

Exhibit 99.1

 

LOGO

Ilumiradxtm Transforming community-based healthcare June 21, 2022


LOGO

Introduction To The Speakers Ron Zwanziger CEO, Co-Founder, Chairman and Director Veronique Ameye Executive Vice President Dorian LeBlanc CFO and Vice President,Global Operations Pooja Pathak Chief Product Officer Matthew Fay Medical Director Jeanne Mumford PathologyManager Johns Hopkins Hospital Pete Grisafi President & CEO Damian Family Care Centers Dr. RogierHopstaken Netherlands GeneralPractitioner Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only. 2


LOGO

Agenda Video and Agenda Colleen McMillen, LumiraDx VP Communications 9:30 – 9:35 Company Overview Ron Zwanziger, LumiraDx CEO 9:35 – 9:50 Dorian LeBlanc, LumiraDx CFO and VP Global Platform Technology and Manufacturing 9:50 – 10:05 Operations Dr. Rogier Hopstaken, Netherlands General Expert Discussion: Enhancing Community Based Practitioner 10:05 – 10:25 Healthcare with POC Dx Dr. Matt Fay, LumiraDx Medical Director Q&A for Ron, Dorian, Rogier, Matt 10:25 – 10:35 Platform Strategy and Pipeline Pooja Pathak, LumiraDx CPO 10:35 – 10:50 Jeanne Mumford, Pathology Manager, Johns Customer Experience: Johns Hopkins University 10:50 – 11:05 Hopkins Hospital Pete Grisafi, President & CEO, Damian Family Care Customer Experience: Damian Family Care Centers Centers 11:05 – 11:20 Dr. Matt Fay, LumiraDx Medical Director Q&A for Pooja, Jeanne, Pete, Matt 11:20 – 11:35 Commercial Strategy and Investment Highlights Veronique Ameye, LumiraDx EVP 11:35 – 11:50 Final questions LumiraDx team 11:50 – 12:00 Close Veronique Ameye, LumiraDx EVP 12:00 3 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Disclaimer FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share, our future results of operations and financial position, business strategy, the Platform, other products, tests, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of LumiraDx Limited (“LumiraDx” or the “Company”) and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of LumiraDx. These forward-looking statements are subject to a number of risks and uncertainties, including our ability to compete in the highly competitive markets in w hich we operate, and potential adverse effects of this competition; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace or adapt to rapidly changing technology, evolving industry standards and changing regulatory environments; uncertainty, downturns and changes in the markets we serve; our expectations regarding the size of the POC market for the Platform, the size of the various addressable markets for certain tests and our ability to penetrate such markets by driving the conversion of healthcare providers’ testing needs onto the Platform; our commercialization strategy, including our plans to initially focus our sales efforts on large healthcare systems, government organizations and national pharmacy chains that want to deploy comprehensive POC testing across their networks, our strategy on the commercialization of our current and future assays and our ability to launch and obtain regulatory approval for new tests; our ability to increase the installed base of our Instruments; our ability to repay or service our debt obligations and meet the financial covenants related to such debt obligations; our belief that we will be able to drive commercialization of the Platform through the launch of our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests; the willingness of healthcare providers to use a POC system over central lab systems and the rate of adoption of the Platform by healthcare providers and other users; the scalability and commercial viability of our manufacturing methods and processes, especially in light of the anticipated demand for the Platform and our minimum commitments to supply the Instrument and test strips in a timely fashion; our ability to maintain our current relationships, or enter into new relationships, w ith diagnostics or research and development companies, third party manufacturers and commercial distribution collaborators; our ability to effectively manage our anticipated growth; our ability to rapidly develop and commercialize diagnostics tests that are accurate and cost-effective; the timing, progress and results of our diagnostic tests, including statements regarding launch plans and commercialization plans for such tests, all which may be delayed by or halted due to a number of factors, including the impact of the COVID-19 pandemic and the end of the COVID-19 pandemic; the timing, scope or likelihood of regulatory submissions, filings, approvals, authorizations, certifications, clinical trials or clearances; the pricing, coverage and reimbursement of the Instrument and tests, if approved; our ability to enforce our intellectual property rights and to operate our business w ithout infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; developments and projections relating to our competitors and our industry; our ability to attract, motivate and retain qualified employees, including members of our senior management team; the effects of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business or operations; social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate, including any impact of the current conflict between Russia and Ukraine; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer; the future trading price of our common shares and impact of securities analysts’ reports on these prices; our ability to fully derive anticipated benefits from existing or future acquisitions, joint ventures, investments or dispositions; exchange rate fluctuations and volatility in global currency markets; potential adverse tax consequences resulting from the international scope of our operations, corporate structure and financing structure; U.S. tax legislation enacted in 2017, which could materially adversely affect our financial condition, results of operations and cash flows; increased risks resulting from our international operations and expectations of future expansion of such operations; our ability to comply w ith various trade restrictions, such as sanctions and export controls, resulting from our international operations; government and agency demand for our products and services and our ability to comply w ith government contracting regulations; our ability to operate in a litigious environment; and those factors discussed under the header “Risk Factors” in the Annual Report on Form 20-F filed by LumiraDx w ith the Securities and Exchange Commission, or SEC, on April 13, 2022 and other filings made by LumiraDx with the SEC. If any of these risks materialize or LumiraDx’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that LumiraDx presently knows or that LumiraDx currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect LumiraDx’s expectations, plans or forecasts of future events and views as of the date of this presentation. LumiraDx anticipates that subsequent events and developments w ill cause LumiraDx’s assessments to change. How ever, while LumiraDx may elect to update these forward-looking statements at some point in the future, LumiraDx specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing LumiraDx’s assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. LumiraDx has no obligation to update this presentation. INDUSTRY AND MARKET DATA This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. LumiraDx believes that these third-party sources and estimates are reliable, but has not independently verified them. LumiraDx’s estimates of the potential market opportunities for its Platform include several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx believes that its own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operates is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by LumiraDx. 4


LOGO

Introduction Ron Zwanziger CEO Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

LumiraDx Today: Transforming Community-based Healthcare PNext Generation POCAddressing the current limitations of legacy POC systemsby bringing lab-comparable performance Diagnostic Companyto the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership PLarge Installed Base with25,000 instruments shipped to 98 countries across primary care, pharmacy, hospital emergency lobal Commercial Reach departments, global health, and other settings PManufacturingAll current and future POC tests are developed on common strip design, enabling flexible, automated and Designed for Scalelow cost manufacturing on a single line. Current manufacturing capacity of 28 Million test strips per month. Poad Menu and Pipeline of Regulatory clearance for 12 tests for use on our Platform,with global TAM of $5B+ (excluding COVID). Diagnostic Tests50+ assays in three-year roadmap* Pxperienced Management Fourth POC company for founding team. Management team has a successful track record Teamof diagnostic innovation and building / scaling companies in POC * Global Total Addressable Market: We estimate each test based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing.6 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Current Point of Care Solutions Have Major Limitations The traditional approach to POC test development has limited scalability and has resulted in ineffective, inefficient and costly solutions Poor clinical performance in areas of high clinical need Coagulation Respiratory Diabetes, Immunoassay Inflammation High cost of total ownership Limited test menu Respiratory Diabetes, Cardiac, Blood Molecular Cardiovascular gas, Metabolic 7 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

We Have Developed and Commercialized an Innovative, Disruptive Solution for POC Testing Lab-comparable Consolidating multiple performance in minutes POC systems onto a single instrument, the LumiraDx Platform is Broad menu of tests designed to be a one-stop on a single instrument solution to transform diagnostic testing and health outcomes around the world Low cost of ownership 8 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Continued Innovation and Platform Expansion Through COVID Offering Recent Updates LumiraDx Platform • CE Mark COVID Ultra test with results in 5 minutes, FDA EUA submission planned @ Point of Care • CE Mark for COVID & Flu A/B, COVID & RSV tests with results in 12 minutes Amira • CE Mark COVID Ag test for first POC application • OTC clinical studies and EUA submission planned for Q3 @ Home and for Screening • Opportunities in respiratory disease, global health, cardiovascular disease • CE Mark COVID & Flu A/B RNA STAR Complete, FDA EUA RNA STAR Complete submission planned @ Fast Lab Solutions • CE Mark COVID RNA STAR Complete Dual Target • Opportunities in respiratory disease, global health, sexual health 9 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Our Platform has Capacity to Target the Global IVD Market Across Sectors Global IVD Market Testing Prices* 5 – 10x Central Lab Near Term Addressable Mid Term Addressable 2 – 3x Central Lab Base Price Central Lab LumiraDx POC Other POC * company estimate Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

11 2022 –2023 Pipeline Plan Note: Regulatory timelines refer to submission dates and launch dates and will be subject to review by corresponding regulatory authorities. Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Unmet Need for High Sensitivity Troponin POC Test Key differential Lab Reference Abbott Architect STAT hs- POC Example POC Example True POC Needs TnI* Siemens Atellica VTLi hs-cTnI* Triage True hsTnI* Aids diagnosis of myocardial Aids diagnosis of myocardial Aids diagnosis of myocardial Aids diagnosis of myocardial Intended Use infarction infarction infarction infarction Regulatory CE Mark, FDA 510K CE Mark, FDA 510K CE Mark CE Mark Authorization Additional Potential 30 day prognosis 30 day prognosis (CE Mark) N/A N/A Claims Limit of Quantitation ≤3.2 ng/L (specification) 2.1 ng/L – plasma 2.1-3.6 ng/L – Plasma ≤ 2.0 ng/L <20% CV 1.5 – 2.9 ng/L (observed) 3.7 ng/L – WB 2.8 ng/L – WB Clinical Sensitivity Whole blood: 2h: 90%+ EDTA Plasma – 2-4h: 90.9% Whole blood—2h: 81.3% EDTA Plasma – 2-4h: 91.9% 2.1 ng/L (plasma)/3.7 ng/L WB to Reportable Range 1.0 – 1,000 ng/L 3.2 to 50,000 ng/L 0.1 ng/L to 1,000 ng/L 1,250 ng/L 210 µL (on-board) Sample size 20µL 30-100 µL 175 µL 10 µL (manual dilution) Capillary WB, venous blood, Plasma & serum (LiHep, K2 & Capillary WB, venous WB & Sample type Venous WB & plasma (EDTA) plasma K3 EDTA) plasma (LiHep) Time to Result 10 min 18 min (time to first result) 8 min 20 min * based on respective company product specifications 12 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Feasibility of High Sensitivity Troponin Results at POC LumiraDx Troponin i 16.0 14.0 12.0 y = 1.0617x—0.0425 R² = 0.9264 (pg/mlL) 10.0 i 8.0 Troponin 6.0 4.0 Troponin i LumiraDX 2.0 0.0 0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 -2.0 Mean Architect Troponin i (pg/mL) Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Platform Technology and Manufacturing Dorian LeBlanc CFO and VP Global Operations Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Next Gen Technology Developed Based on Laboratory Precise sample fluidic control, on strip position sensors Gas wash to reduce sample matrix bias Calibration to lab standard System controls cover strip positioning, electronics, optics, temperature, hematocrit and Test Strip expiry Multiple test technologies inc. immunoassay, enzyme, molecul electrolytes/blood gas, clinical chemistry and hematology Multiple sample types inc. nasal, blood, urine, vaginal Connectivity enables remote management and configurations Instruments, view test results and simplify workgroup provisioni 15 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

IP Ring-Fence Model for POC Platform Protected by issues and pending patents and know-how including: • At least 15 U.S. patents • At least 100 foreign patents • 11 pending U.S. non-provisional patent applications • At least 5 pending PCT patent applications • At least 50 pending foreign patent applications • 2 pending U.S. provisional applications 16 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Microfluidic Immunofluorescence Technology Drives High Sensitivity At POC 8 Results Displayed Sample and Any Unbound 4 Sandwich Assay Binding Assay Binding View 6 Label Removed Using Air Sample and Reagents Actively Mixed Mag Particle Fluorescent Latex in Channels Mag Latex 3 Magnet 2 RESULTS IN MINUTES Active Fluidics 1 Move Sample Optical Reader Engine Sample Added Magnet Magnet 5 Magnetic Field Captures Bound Particles 7 Dry, Clear Fluorescent Signal Measured 17 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Delivers Speed and Performance on a True Point of Care Platform Many Diagnostic Assays Room Temperature > Single Platform Consumable Storage Lab Performance and Fast Results in Quality Oversight Minutes Portable, Seamless All Common Connectivity Clinical Samples One Simple, Intuitive Built on a Low Cost, High Test Workflow Volume MFD Platform 18 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Simple and Common Strip Design 19 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Manufacturing Video Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Expert Discussion: Enhancing Community Based Healthcare with POC Dx Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Q&A Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Platform Strategy and Pipeline Pooja Pathak Chief Product Officer Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Platform Strategy Focused on Improving and Expanding the POC Testing Experience Raise the standard for POC testing Performance, Speed, Access and Experience Consolidate multiple POC instruments to a single lab comparable platform Develop comprehensive test menus by Disease and care setting 24 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

1 Raise the Standard for POC Testing Performance, Speed, Access and Experience Example: Rule of Venous Thromboembolism with LumiraDx D-Dimer test • High sensitivity and Speed: ULTRA product line delivers high sensitivity results for respiratory disease diagnosis, taking test times from 15-30 minutes down to 5 minutes • Easy sample collection: Only quantitative fingerstick blood-based tests for D-Dimer and NT-ProBNP to aid diagnosis in community settings • Built to expand access: Portable system (2.2 lbs, low footprint, battery operated, room temp reagents) • 99.5% negative predictive value at the 500 ug/L cut off, and cloud-based connectivity enables centrally when used in combination with a pretest probability score managed program in the community • Fingerstick sample, results in 6minutes • Strong correlation with the laboratory reference, in particular around the clinically relevant values of <750 `lg/L FEU 25 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


 

LOGO

1 Introducing High Sensitivity Respiratory Recent Updates Testing with Ultra => Results in 5 minutes High sensitivity: COVID Ultra PPA 98.6% at Ct <33; 96.0% at Ct<35 Fast results: 5 minutes from sample application Full respiratory pipeline: COVID, Flu A/B, RSV, Strep A Grouping N PPA 95% CI Ct < 35 (all) 149 96.0% [91.5%,98.1%] Ct < 33 (all) 141 98.6% [95.0%,99.6%] Ct < 30 (all) 128 98.4% [94.5%,99.6%] Ct < 25 (all) 91 98.9% [94.0%,99.8%] 26 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

1 Significant Progress in Meeting Recent Updates Community Based Testing Needs Application Antimicrobial Rule out of Venous Coagulation Heart Failure Diabetes stewardship Thromboembolism monitoring diagnosis Monitoring TAM* $300M $700M $500M $350M $1.3B POC Fingerprick sample, Fingerprick sample, Fingerprick sample, Fingerprick sample, Fingerprick sample, Specifications results in 4min results in 6min results in 1min results in 12min results in 7min Commercial Commercially Commercially Commercially CE Mark CE Mark Status* Available Available Available Expected H2 2022 Launch Expected H2 2022 Launch 27 * Global Total Addressable Market: We estimated for each test based on our current assumptions, including the (a) existing mark et sizes, (b) central lab market that could move to the POC, and (c) expansion of diagnostic testing. Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

2 Consolidate Multiple POC Instruments to a Single Lab Comparable Platform x x x Coagulation Respiratory Diabetes, Respiratory Diabetes, Cardiac, Blood gas, Immunoassay Inflammation Molecular Cardiovascular Metabolic NEAR TERM 18-24 MONTHS Able to move most European customers from Able to move most US and European customers 3 => 1 Platform with INR, COVID Ag, Flu A/B, 6 => 1 Platform with US authorizations and RSV, CRP and HbA1c addition of molecular respiratory, lipids, electrolytes, and cardiac content 28 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

2 Builds Broad Testing Menu and Volumes Per Customer Illustration: Germany GP Office Group Total GP and LumiraDx Revenue Per Year Illustrative year 1 volume reimvursement revenue Illustrative year 1 volume reimvursement revenue Illustrative year 1 volume reimvursement revenue Coagulation inr d-dimer diabetes hba1c creatinine Respiratory covid ultra covid&flu Cardiovascular nt-probnp troponin total gp revenue total lumiradx revenue 600 5.29 3,171 5.29 3,171 600 5.29 120 5.76 691 Note: Represents a disruptive pricing strategy to enable rapid adoption of multiple parameters on the instrument, with $20K revenue per instrument for the GP office in Year 1. Illustrative numbers are not projections; they are goals and are forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. For discussion of some of the important factors that could cause these variations, please consult the “Risk Factors” in the Annual Report on 20-F filed by LumiraDx with the SEC. Nothing in this presentation should be regarded as a representation by any person that these goals will be achieved and the Company undertakes no duty to update its goals. 29 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

3 Note: Regulatory timelines refer to submission dates and launch dates will be subject to review by corresponding regulatory authorities. 30 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

3 Develop Comprehensive Test Menus By Disease and Care Setting * Items marked in bold are the 12 diagnostic tests for which we have obtained regulatory approval, authorization, certification or clearance 31 for use on our Platform Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Customer Experience: Johns Hopkins University Jeanne Mumford Pathology Manager, Johns Hopkins Hospital Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Customer Experience: Damian Family Care Centers Pete Grisafi, President & CEO, Damian Family Care Centers Dr. Matt Fay, LumiraDx Medical Director Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Q&A Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Commercial Strategy and Investment Highlights Veronique Ameye EVP Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Global Commercial Footprint and Platform Placements to Drive Penetration of TAM* • 1600+ employees, of which >200 are commercial employees located in 27 countries • Direct sales operations in Western Europe, USA, Japan, Colombia, Brazil, India and Africa • Distribution in another >30 countries. Total reach ~100 countries • Over time, plan to operate with a direct commercial presence in each of the largest diagnostics markets, including China, South Korea, Southeast Asia and Latin America to ensure broad access of our Platform globally Instrument Placement Locations * as of March 2022 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Customer Focused Growth Strategy: Near-Term Opportunities Physician Office / Pharmacy Acute / Emergency Care Global Health Instruments 8,500+ 5,400+ 5,100+ shipped* US and Global Strategic Partner Health Systems COVID Antigen / Ultra  Flu A/B + COVID  HS Troponin RSV + COVID-19  TB Molecular BNP Strep A Molecular HIV Viral Load D-Dimer  CRP  COVID Antigen / Ultra  NT-proBNP Key Products** HbA1c  CRP  COVID Antigen / Ultra  INR  D-Dimer  Flu A/B + COVID Na/K INR  RSV + COVID-19 Lipids HbA1c  Procalcitonin D-Dimer NT-ProBNP *Total instrument shipments are 25,000+ with 6,000+ estimated for use in COVID screening applications with future testing nee ds to be determined **Tests critical to launch in customer segment are bolded; tests currently available in initial market are checked  Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Strong Leadership Team Management Experience Ron Zwanziger Dave Scott, Ph.D. Jerry McAleer, Ph.D. Nigel Lindner, Ph.D. CEO, Co-Founder, Chief Technology Officer, Chief Scientist, Chief Innovation Chairman and Director Co-Founder and Director Co-Founder and Director Officer Tom Quinlan David Walton, D.M.S. Peter Scheu Veronique Ameye General Manager, Chief Commercial President, North American Executive Vice President Health IT Officer Commercial Operations and General Counsel Dorian LeBlanc, C.P.A. Pooja Pathak CFO and Vice President, Chief Product Officer Global Operations Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

LumiraDx Today: Transforming Community-based Healthcare P Next Generation POC Addressing the current limitations of legacy POC systems by bringing lab-comparable performance Diagnostic Company to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership P Large Installed Base with 25,000 instruments shipped to 98 countries across primary care, pharmacy, hospital emergency lobal Commercial Reach departments, global health, and other settings P Manufacturing All current and future POC tests are developed on common strip design, enabling flexible, automated and Designed for Scale low-cost manufacturing on a single line. Current manufacturing capacity of 28Million test strips per month. P Broad Menu and Pipeline Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID). of Diagnostic Tests 50+ assays in three-year roadmap P Experienced Fourth POC company for founding team. Management team has a successful track record Management Team of diagnostic innovation and building / scaling companies in POC 39 Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Q&A Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.


LOGO

Confidential and Proprietary Copyright © 2022 LumiraDx Ltd. All Rights Reserved, Worldwide. For discussion purposes only.